Move follows acquisition of Vesta and creates fully integrated CDMO focusing on advanced drug delivery and combination products
Lubrizol LifeSciences, a supplier of advanced materials for the healthcare industry, has formed an alliance with drug development services provider Particle Sciences to offer customers a range of materials, drug development and commercial manufacturing services.
Lubrizol’s recent acquisition of contract manufacturer Vesta, in combination with this new alliance, means that the LifeSciences business now offers complete solutions for sustained, controlled release and combination products from polymer supply and drug product development to quality manufacturing services.
'We’ve broadened our offering and further reinforced our commitment to the pharmaceutical market,' says Jean Claude Deneuville, Lubrizol LifeSciences Director of the Pharma Solutions business. 'By joining forces with Vesta and working with Particle Sciences, we have further expanded our set of skills and brought full-service solutions to the market.'
Particle Sciences, based in Bethlehem, PA, offers a suite of services including analytic, bio-analytic, physical characterisation and manufacturing, all focused on the formulation and support of advanced drug delivery solutions.
The recent acquisition of Vesta, headquartered in Franklin, WI, broadens Lubrizol's life science manufacturing capabilities, applications and material portfolio with access to silicone polymers and a variety of thermoplastics used in medical devices, advanced wound care and drug eluting products such as subcutaneous implants.